What is IMFINZI and How Does IMFINZI Work? What is IMFINZI and How Does IMFINZI Work?

It is not known if IMFINZI is safe and effective in children.

What is IMFINZI?

IMFINZI® (durvalumab) is a prescription medicine used to treat adults with a type of cancer in the bladder and urinary tract called urothelial carcinoma. IMFINZI may be used when your urothelial carcinoma has spread or cannot be removed by surgery, and chemotherapy containing platinum did not work or is no longer working. IMFINZI was FDA approved for this use based on a clinical study that measured how many patients responded and how long they responded. The study is ongoing to confirm clinical benefit.

It is not known if IMFINZI is safe and effective in children.

IMFINZI is not a chemotherapy—IMFINZI is an immunotherapy

IMFINZI is an immunotherapy—a type of cancer treatment that works with your immune system to find and attack cancer cells. There is a chance that IMFINZI may affect healthy cells, too.

TO UNDERSTAND HOW IMFINZI WORKS, IT’S IMPORTANT TO UNDERSTAND THE KEY PLAYERS:

Key players in your immune system
Immune system identifying and attacking cancer cells

When cancer cells appear in your body, your immune system works to recognize and attack them.

PD-L1 disguises cancer cells from your immune system to look healthy

PD-L1 is a protein that disguises cancer cells from the immune system.

IMFINZI works by blocking PD-L1 to remove the disguise

IMFINZI works by blocking PD-L1 to remove the disguise…

Immune system is now better able to find and attack cancer cells

…so your immune system is better able to find and attack these cancer cells. There is a chance that IMFINZI may affect healthy cells, too.

It is not known if IMFINZI is safe and effective in children.

Important Safety Information

What is the most important information I should know about IMFINZI?

IMFINZI is a medicine that may treat a type of cancer in the bladder and urinary tract or certain types of lung cancer by working with your immune system.

IMFINZI can cause your immune system to attack normal organs and tissues and can affect the way they work. These problems can sometimes become serious or life-threatening and can lead to death.

What is IMFINZI?

IMFINZI® (durvalumab) is a prescription medicine used to treat adults with a type of cancer in the bladder and urinary tract called urothelial carcinoma. IMFINZI may be used when your urothelial carcinoma has spread or cannot be removed by surgery, and chemotherapy containing platinum did not work or is no longer working. IMFINZI was FDA approved for this use based on a clinical study that measured how many patients responded and how long they responded. The study is ongoing to confirm clinical benefit.

It is not known if IMFINZI is safe and effective in children.

Call or see your healthcare provider right away if you develop any symptoms of the following problems or if these symptoms get worse:

  • Lung problems icon

    Lung problems (pneumonitis). Signs and symptoms may include new or worsening cough, shortness of breath, and chest pain.

  • Liver problems icon

    Liver problems (hepatitis). Signs and symptoms may include yellowing of your skin or the whites of your eyes, severe nausea or vomiting, pain on the right side of your stomach area (abdomen), drowsiness, dark urine (tea colored), bleeding or bruising more easily than normal, and feeling less hungry than usual.

  • Intestinal problems icon

    Intestinal problems (colitis). Signs and symptoms may include diarrhea or more bowel movements than usual; stools that are black, tarry, sticky, or have blood or mucus; and severe stomach-area (abdomen) pain or tenderness.

  • Hormone gland problems icon

    Hormone gland problems (especially the thyroid, adrenals, pituitary, and pancreas). Signs and symptoms that your hormone glands are not working properly may include headaches that will not go away or unusual headaches; extreme tiredness; weight gain or weight loss; dizziness or fainting; feeling more hungry or thirsty than usual; hair loss; feeling cold; constipation; your voice gets deeper; urinating more often than usual; nausea or vomiting; stomach-area (abdomen) pain; and changes in mood or behavior, such as decreased sex drive, irritability, or forgetfulness.

  • Kidney problems icon

    Kidney problems, including nephritis and kidney failure. Signs of kidney problems may include decrease in the amount of urine, blood in your urine, swelling of your ankles, and loss of appetite.

  • Skin problems icon

    Skin problems. Signs may include rash, itching, and skin blistering.

  • Other organ problems icon

    Problems in other organs. Signs and symptoms may include neck stiffness; headache; confusion; fever; chest pain, shortness of breath, or irregular heartbeat (myocarditis); severe or persistent muscle pain; severe muscle weakness; changes in mood or behavior; low red blood cells (anemia); excessive bleeding or bruising; blurry vision, double vision, or other vision problems; and eye pain or redness.

  • Severe infections icon

    Severe infections. Signs and symptoms may include fever, cough, frequent urination, pain when urinating, and flu-like symptoms.

  • Severe infusion reactions icon

    Severe infusion reactions. Signs and symptoms may include chills or shaking, itching or rash, flushing, shortness of breath or wheezing, dizziness, fever, feeling like passing out, back or neck pain, and facial swelling.

Getting medical treatment right away may help keep these problems from becoming more serious. Your healthcare provider will check you for these problems during your treatment with IMFINZI. Your healthcare provider may treat you with corticosteroid or hormone replacement medicines. Your healthcare provider may delay or completely stop treatment with IMFINZI if you have severe side effects.

Before you receive IMFINZI, tell your healthcare provider about all of your medical conditions, including if you have immune system problems such as Crohn’s disease, ulcerative colitis, or lupus; have had an organ transplant; have lung or breathing problems; have liver problems; or are being treated for an infection.

If you are pregnant or plan to become pregnant, tell your healthcare provider. IMFINZI can harm your unborn baby. If you are able to become pregnant, you should use an effective method of birth control during your treatment and for at least 3 months after the last dose of IMFINZI. Talk to your healthcare provider about which birth control methods to use. Tell your healthcare provider right away if you become pregnant during treatment with IMFINZI.

If you are breastfeeding or plan to breastfeed, tell your healthcare provider. It is not known if IMFINZI passes into breast milk. Do not breastfeed during treatment with IMFINZI and for at least 3 months after the last dose of IMFINZI.

Tell your healthcare provider about all the medicines you take. This includes prescription and over-the-counter medicines, vitamins, and herbal supplements.

What are the possible side effects of IMFINZI?

IMFINZI can cause serious side effects (see above).

The most common side effects in people with urothelial carcinoma include feeling tired, muscle or bone pain, constipation, decreased appetite, nausea, swelling of your arms and legs, and urinary tract infection.

Tell your doctor if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of IMFINZI. Ask your healthcare provider or pharmacist for more information.

Call your healthcare provider for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

You may report side effects related to AstraZeneca products by clicking here.

What is IMFINZI?

IMFINZI® (durvalumab) is a prescription medicine used to treat adults with a type of cancer in the bladder and urinary tract called urothelial carcinoma. IMFINZI may be used when your urothelial carcinoma has spread or cannot be removed by surgery, and chemotherapy containing platinum did not work or is no longer working. IMFINZI was FDA approved for this use based on a clinical study that measured how many patients responded and how long they responded. The study is ongoing to confirm clinical benefit.

It is not known if IMFINZI is safe and effective in children.

Please see complete Prescribing Information, including Patient Information (Medication Guide).